Slideshows Images Quizzes


Last reviewed on RxList: 12/29/2016
Dantrium Side Effects Center

Last reviewed on RxList 12/19/2015

Dantrium Intravenous (dantrolene sodium) is a skeletal muscle relaxant mainly used in as an emergency treatment for malignant hyperthermia, which is a rare reaction to medications (mainly anesthetics). Dantrium Intravenous is available in generic form. Common side effects of Dantrium Intravenous include muscle weakness, drowsiness, dizziness, low energy, tired feeling, injection site reactions (pain, redness, or swelling), diarrhea, constipation, nausea, vomiting, stomach pain, problems with speech, difficulty with balance or walking, headache, confusion, vision problems, sleep problems (insomnia), sweating, drooling, or urinating more than usual.

Dantrium Intravenous should be administered by continuous rapid intravenous push beginning at a minimum dose of 1 mg/kg, and continuing until symptoms subside or the maximum cumulative dose of 10 mg/kg has been reached. Dantrium Intravenous may interact with calcium channel blockers, or vecuronium-induced neuromuscular blocks. Tell your doctor all medications and supplements you use. During pregnancy, Dantrium Intravenous should be used only if prescribed. This drug passes into breast milk. Consult your doctor before breastfeeding.

Our Dantrium Intravenous (dantrolene sodium) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Dantrium Professional Information


There have been occasional reports of death following malignant hyperthermia crisis even when treated with intravenous dantrolene; incidence figures are not available (the pre-dantrolene mortality of malignant hyperthermia crisis was approximately 50%). Most of these deaths can be accounted for by late recognition, delayed treatment, inadequate dosage, lack of supportive therapy, intercurrent disease and/or the development of delayed complications such as renal failure or disseminated intravascular coagulopathy. In some cases there are insufficient data to completely rule out therapeutic failure of dantrolene.

There are reports of fatality in malignant hyperthermia crisis, despite initial satisfactory response to i.v. dantrolene, which involve patients who could not be weaned from dantrolene after initial treatment.

The administration of intravenous Dantrium to human volunteers is associated with loss of grip strength and weakness in the legs, as well as drowsiness and dizziness.

The following adverse reactions are in approximate order of severity:

There are rare reports of pulmonary edema developing during the treatment of malignant hyperthermia crisis in which the diluent volume and mannitol needed to deliver i.v. dantrolene possibly contributed.

There have been reports of thrombophlebitis following administration of intravenous dantrolene; actual incidence figures are not available. Tissue necrosis secondary to extravasation has been reported.

There have been rare reports of urticaria and erythema possibly associated with the administration of i.v. Dantrium. There has been one case of anaphylaxis.

Injection site reactions (pain, erythema, swelling), commonly due to extravasation, have been reported.

None of the serious reactions occasionally reported with long-term oral Dantrium use, such as hepatitis, seizures, and pleural effusion with pericarditis, have been reasonably associated with short-term Dantrium Intravenous therapy.

The following events have been reported in patients receiving oral dantrolene: aplastic anemia, leukopenia, lymphocytic lymphoma, and heart failure. (See package insert for Dantrium (dantrolene sodium) Capsules for a complete listing of adverse reactions.)

The published literature has included some reports of Dantrium use in patients with Neuroleptic Malignant Syndrome (NMS). Dantrium Intravenous is not indicated for the treatment of NMS and patients may expire despite treatment with Dantrium Intravenous.

Read the entire FDA prescribing information for Dantrium (Dantrolene Sodium for Injection)

Related Resources for Dantrium

© Dantrium Patient Information is supplied by Cerner Multum, Inc. and Dantrium Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors